Impact of isolated germline JAK2V617I mutation on human hematopoiesis

Blood

Volumn 121, Issue 20, 2013, Pages 4156-4165

  Mead, Adam J ^a   Chowdhury, Onima ^a   Pecquet, Christian ^b   Dusa, Alexandra ^b   Woll, Petter ^a   Atkinson, Deborah ^a   Burns, Adam ^c   Score, Joannah ^d   Rugless, Michelle ^c   Clifford, Ruth ^c   Moule, Simon ^e   Bienz, Nicola ^e   Vyas, Paresh ^a   Cross, Nick ^d   Gale, Rosemary E ^f   Henderson, Shirley ^c   Constantinescu, Stefan N ^b   Schuh, Anna ^c   Jacobsen, Sten Eirik W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b DE DUVE INSTITUTE   (Belgium)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e WEXHAM PARK HOSPITAL   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; COMPLEMENTARY DNA; D835 PROTEIN; DNA METHYLTRANSFERASE 3A; ERYTHROPOIETIN; FLT3 LIGAND; GENOMIC DNA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; KIT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NUCLEOPHOSMIN; PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STEM CELL FACTOR; TET2 PROTEIN; THROMBOPOIETIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; ISOLEUCINE; JAK2 PROTEIN, HUMAN; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CLONAL VARIATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RESPONSE; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GERMLINE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MOUSE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTOSIS; WHOLE EXOME SEQUENCING; XENOTRANSPLANTATION; ADULT; AMINO ACID SUBSTITUTION; ANIMAL; CELL CULTURE; FAMILY; FEMALE; GENETICS; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDER; NONOBESE DIABETIC MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ADULT; AMINO ACID SUBSTITUTION; ANIMALS; CELLS, CULTURED; FAMILY; FEMALE; GERM-LINE MUTATION; HEMATOPOIESIS; HUMANS; ISOLEUCINE; JANUS KINASE 2; MALE; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; VALINE;

MLCS; MLOWN;

EID: 84880541262     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-430926     Document Type: Article

References (51)

1. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
2. Cross NC. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2011;2011:208-214.
3. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723-1735.
4. Li J, Kent DG, Chen E, Green AR. Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech. 2011;4(3):311-317.
5. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106(6): 2162-2168.
6. Szpurka H, Tiu R, Murugesan G, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood. 2006;108(7):2173-2181.
7. Lee JW, Kim YG, Soung YH, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene. 2006;25(9):1434-1436.
8. Xu X, Zhang Q, Luo J, et al. JAK2(V617F): Prevalence in a large Chinese hospital population. Blood. 2007;109(1):339-342.
9. Gale RE, Allen AJ, Nash MJ, Linch DC. Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. Blood. 2007;109(3):1241-1243.
10. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108(4):1377-1380.
11. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35(1):32-38.
12. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007;110(1):375-379.
13. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 2003;102(10):3793-3796.
14. Bellanné-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108(1):346-352.
15. Rumi E. Familial chronic myeloproliferative disorders: the state of the art. Hematol Oncol. 2008;26(3):131-138.
16. Teofili L, Larocca LM. Advances in understanding the pathogenesis of familial thrombocythaemia. Br J Haematol. 2011;152(6):701-712.
17. Jamieson CH, Gotlib J, Durocher JA, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA. 2006;103(16):6224-6229.
18. Anand S, Stedham F, Beer P, et al. Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood. 2011;118(1):177-181.
19. Li J, Spensberger D, Ahn JS, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood. 2010;116(9):1528-1538.
20. Mullally A, Lane SW, Ball B, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17(6):584-596.
21. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115(17):3589-3597.
22. Marty C, Lacout C, Martin A, et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood. 2010;116(5):783-787.
23. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940.
24. Kubovcakova L, Lundberg P, Grisouard J, et al. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood. 2013;121(7):1188-1199.
25. Mead AJ, Rugless MJ, Jacobsen SE, Schuh A. Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med. 2012;366(10):967-969.
26. Etheridge L, Corbo LM, Kaushansky K, Chan E, Hitchcock IS. A novel activating JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis (fET) via mechanisms distinct from JAK2V617F [abstract]. Blood. 2011;118(21):60a.
27. Rumi E, Harutyunyan A, Pietra D, et al. A novel germline JAK2 mutation in familial thrombocytosis [abstract]. Haematologica. 2012;97(s1):244a.
28. Wang L, Swierczek S, Piterkova L, Hickman K, Wheeler D, Prchal J. Whole exome sequencing of polycythemia vera reveals novel recurrent somatic and germline variation [abstract]. Blood. 2012;120(21):705a.
29. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722-726.
30. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113(24):6182-6192.
31. Scholl S, Mügge LO, Landt O, Loncarevic IF, Kunert C, Clement JH, et al. Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia. Leuk Res. 2007;31(9):1205-1211.
32. Kiyoi H, Naoe T, Yokota S, et al; Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia. 1997;11(9):1447-1452.
33. Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5(2):96-102.
34. Gelsi-Boyer V, Trouplin V, Adélaïde J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6):788-800.
35. Felsberg J, Wolter M, Seul H, Friedensdorf B, Göppert M, Sabel MC, et al. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol. 2010;119(4):501-507.
36. Zhao W, Bueso-Ramos CE, Verstovsek S, Barkoh BA, Khitamy AA, Jones D. Quantitative profiling of codon 816 KIT mutations can aid in the classification of systemic mast cell disease. Leukemia. 2007;21(7):1574-1576.
37. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365-386.
38. Haywood A, Dreau H, Timbs A, Schuh A, Old J, Henderson S. Screening for clinically significant non-deletional alpha thalassaemia mutations by pyrosequencing. Ann Hematol. 2010;89(12):1215-1221.
39. Lunter G, Goodson M. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. Genome Res. 2011;21(6):936-939.
40. Majeti R, Park CY, Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell. 2007;1(6):635-645.
41. Dusa A, Staerk J, Elliott J, Pecquet C, Poirel HA, Johnston JA, et al. Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J Biol Chem. 2008;283(19):12941-12948.
42. Seubert N, Royer Y, Staerk J, et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell. 2003;12(5):1239-1250.
43. Pecquet C, Staerk J, Chaligné R, et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood. 2010;115(5):1037-1048.
44. Staerk J, Defour JP, Pecquet C, et al. Orientation-specific signalling by thrombopoietin receptor dimers. EMBO J. 2011;30(21):4398-4413.
45. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39(Database issue): D945-D950.
46. Liu K, Martini M, Rocca B, et al. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica. 2009;94(10):1368-1374.
47. Schnittger S, Bacher U, Haferlach C, et al. Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica. 2009;94(1):141-144.
48. Lee TS, Ma W, Zhang X, Kantarjian H, Albitar M. Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations. BMC Struct Biol. 2009;9:58.
49. Chen E, Beer PA, Godfrey AL, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell. 2010;18(5):524-535.
50. Qian H, Buza-Vidas N, Hyland CD, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell. 2007;1(6):671-684.
51. Buza-Vidas N, Antonchuk J, Qian H, et al. Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. Genes Dev. 2006;20(15):2018-2023.